DIA 2013 49th Annual Meeting
Click here to go to the previous page
Developing and Embracing a Culture of Quality in the Pharmaceutical Industry
Track : Track 12: Pharmaceutical Quality
Program Code: 216
Date: Tuesday, June 25, 2013
Time: 8:00 AM to 9:30 AM  EST
Location: 153C
CHAIR :
 Mary Oates, PhD (SCHNON), Vice President, Global Quality Operations and EHS, Pfizer Inc, United States
SPEAKER (S):
 Christine M. V. Moore, PhD (SPKAGY), Acting Director, Office of New Drug Quality Assessment, OPS, CDER, FDA, United States
 Guy Villax, (SPKNON), Chief Executive Officer, Hovione, Portugal
 David A. Tainsh, PhD,RPh (SPKNON), Chief Product Quality Officer, Governance, Ethics and Assurance, GlaxoSmithKline, United Kingdom
Description
Reliable availability of quality medicines requires more than following the rules laid down by regulators. Today's complex, global environment demands that all participants in the supply chain adopt a culture of quality, a culture in which every employee understands and embraces their responsibility for delivering quality outcomes that benefit patients. This focus on quality outcomes must exist across the product life cycle, including product and process development, clinical trials, regulatory submissions and commercial manufacturing. The session will define the characteristics of a quality culture across a range of firms and functions, describe how to assess existing culture and achieve the desired state and outline the benefits for patients, regulators and the pharmaceutical industry.